Invivyd (IVVD) Share-based Compensation (2020 - 2025)
Invivyd (IVVD) posted Share-based Compensation of $2.6 million for Q4 2025, down 79.81% on a QoQ basis from $12.7 million in Q3 2025, and down 16.13% year-over-year from $3.1 million in Q4 2024.
Invivyd (IVVD) Share-based Compensation (2020 - 2025) Analysis & Trends
Invivyd's Share-based Compensation history runs 6 years deep, the most recent figure standing at $2.6 million for Q4 2025.
- Quarterly Share-based Compensation fell 16.13% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.7 million (down 41.05% YoY) and the FY2025 annual result came in at $11.6 million, down 41.16% from the prior year.
- Share-based Compensation was $2.6 million for Q4 2025 at Invivyd, down from $12.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $19.9 million in Q4 2022 and bottomed at -$9.9 million in Q4 2021.
- A 5-year average of $5.6 million and a median of $4.5 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation slumped 10008.0% — and 2025, when it surged 343.13%.
- Invivyd's Share-based Compensation stood at -$9.9 million in 2021, then jumped by 301.05% to $19.9 million in 2022, then sank by 78.19% to $4.3 million in 2023, then retreated by 29.63% to $3.1 million in 2024, then retreated by 16.13% to $2.6 million in 2025.
- Business Quant data shows IVVD's Share-based Compensation at $2.6 million in Q4 2025, $12.7 million in Q3 2025, and $3.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | 305,000.00 |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | - |
| 10 | Invivyd | 104.45 Mn | -122.24 Mn | 16.07 Mn | 2.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.56 Mn |
| Dec 31, 2025 | 2.56 Mn |
| Sep 30, 2025 | 12.70 Mn |
| Sep 30, 2025 | 12.70 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 31, 2025 | 19.00 Mn |
| Mar 31, 2025 | 19.00 Mn |
| Dec 31, 2024 | 3.06 Mn |
| Dec 31, 2024 | 3.06 Mn |
| Sep 30, 2024 | 2.87 Mn |
| Sep 30, 2024 | 2.87 Mn |
| Jun 30, 2024 | 8.49 Mn |
| Jun 30, 2024 | 8.49 Mn |
| Mar 31, 2024 | 5.38 Mn |
| Mar 31, 2024 | 5.38 Mn |
| Dec 31, 2023 | 4.34 Mn |
| Dec 31, 2023 | 4.34 Mn |
| Sep 30, 2023 | 4.26 Mn |
| Sep 30, 2023 | 4.26 Mn |